Journals Critical Reviews in Oncology/h...

Critical Reviews in Oncology/hematology
Songqing Fan, Hongmei Zheng, Yue Xu, Yuting Zhan, Jiadi Luo, Hongjing Zang, Huilin Wang, Weiyuan Wang, Yue Xu
Head and neck squamous cell carcinomas (HNSCC) constitute a heterogeneous cluster of tumors celebrated for their predisposition to metastasize and exhibit local recurrence. Recent explorations have illuminated the intricate involvement of Somatostatin Receptor 2 (SSTR2), a growth-regulatory receptor traditionally classified as a tumor suppressor, yet concurrently implicated in bolstering specific tumor phenotypes. Advances in the realm of SSTR2 investigation within HNSCC, with a specific spotlight on laryngeal squamous cell carcinomas (LSCC), tongue squamous cell carcinomas (TSCC), and nasopharyngeal carcinomas (NPC), have been established...
November 28, 2023: Critical Reviews in Oncology/hematology
Jiaran Zhang, Huichun Tian, Lili Mao, Lu Si
Targeted therapies revolutionized the management of patients with advanced and metastatic cutaneous melanoma. However, despite recent advances in the understanding of the molecular drivers of melanoma and its treatment with targeted therapies, patients with rare and aggressive melanoma subtypes, including acral melanoma (AM) and mucosal melanomas (MM), show limited long-term clinical benefit from current targeted therapies. While patients with AM or MM and BRAF or KIT mutations may benefit from targeted therapies, the frequency of these mutations is relatively low, and there are no genotype-specific treatments for most patients with AM or MM who lack common driver mutations...
November 28, 2023: Critical Reviews in Oncology/hematology
Juyue Zhou, D U Zhonghai, Yan Liang, Sensen Zhang
The development of immune checkpoint inhibitors(ICIs) has revolutionized the progress of solid tumors. Ongoing clinical trials are exploring the use of checkpoint inhibitors in recurrent small-cell lung cancer and achieving specific results. Although studies have been conducted to systematically review this issue, we conducted this single-arm meta-analysis in light of the emergence of several new clinical studies. In total, 1096 individuals from 11 clinical investigations were enrolled in this single-arm meta-analysis...
November 28, 2023: Critical Reviews in Oncology/hematology
Daniele Fanale, Lidia Rita Corsini, Marco Bono, Ugo Randazzo, Nadia Barraco, Chiara Brando, Daniela Cancelliere, Silvia Contino, Ambra Giurintano, Luigi Magrin, Erika Pedone, Alessandro Perez, Paola Piraino, Alessia Pivetti, Emilia Di Giovanni, Tancredi Didier Bazan Russo, Ornella Prestifilippo, Vincenzo Gennusa, Gianni Pantuso, Antonio Russo, Viviana Bazan
Specific tumor-derived extracellular vesicles, called exosomes, are considered as potential key players in cross-talk between immune system and tumor microenvironment in several solid tumors. Different studies highlighted the clinical relevance of exosomes in ovarian cancer (OC) for their role in early diagnosis, prognosis, chemoresistance, targeted therapy. The exosomes are nanosize vesicles carrying lipids, proteins, and nucleic acids. In particular, exosomes shuttle a wide spectrum of microRNAs (miRNAs) able to induce phenotypic reprogramming of target cells, contributing to tumor progression...
November 28, 2023: Critical Reviews in Oncology/hematology
Jingjing Xi, Kai Liu, Zhaolei Peng, Xiaolin Dai, Yulin Wang, Chunyan Cai, Dejun Yang, Chunmei Yan, Xiaofang Li
Glioblastoma is a fatal intracranial tumor with a poor prognosis, exhibiting uninterrupted malignant progression, widespread invasion throughout the brain leading to the destruction of normal brain tissue and inevitable death. Monoclonal antibodies alone or conjugated with cytotoxic payloads to treat patients with different solid tumors showed effective. This treatment strategy is being explored for patients with glioblastoma (GBM) to obtain meaningful clinical responses and offer new drug options for the treatment of this devastating disease...
November 28, 2023: Critical Reviews in Oncology/hematology
Tongze Cai, Liuguan Liang, Xingxing Zhao, Caiyue Lin, Dandan Li, Jinghui Zheng
INTRODUCTION: This article provided direct comparisons across first-line regimens for patients with human epidermal growth factor receptor 2 (HER2)-negative advanced gastric cancer. We performed a network meta-analysis (NMA) of phase III trials to compare the efficacy and safety of first-line treatments for gastric cancer. METHODS: We conducted a systematic review and Bayesian or Frequentist network meta-analysis by searching relevant literature from PubMed, EMBASE, Cochrane Library, ClinicalTrials...
November 27, 2023: Critical Reviews in Oncology/hematology
Jorge Balaguer, Jesús García-Foncillas, José Tuñón
The connection between heart failure (HF) and cancer through multiple pathways such as inflammation, oxidative stress, and neurohormonal activation, among others, is well established. As a consequence, increases in plasma levels of several biomarkers have been described in both disorders. The most consistent information is related to natriuretic peptides (NPs). Although they are known to be produced in the ventricles as a response to myocardial distension, and thus can be useful for the diagnosis and prognosis of HF, and also for the management of chemotherapy-induced myocardial damage, they are also produced by tumour cells...
November 27, 2023: Critical Reviews in Oncology/hematology
Maria D Hurtado, Elif Tama, Stacey D'Andre, Chrisandra Shufelt
BACKGROUND: Breast cancer (BC) is the most common cancer in women. While the combination of improved screening, earlier detection, and advances in therapeutics has resulted in lower BC mortality, BC survivors are now increasingly dying of cardiovascular disease. Cardiovascular disease in the leading cause of non-cancer related mortality among BC survivors. This situation underscores the critical need to research the role of modifiable cardiometabolic risk factors, such as excess adiposity, that will affect BC remission, long-term survivorship, and overall health and quality of life...
November 24, 2023: Critical Reviews in Oncology/hematology
L Rached, A Geraud, M Frelaut, Z Ap Thomas, V Goldschmidt, G Beraud-Chaulet, C Nagera-Lazarovici, F X Danlos, C Henon, C Parisi, A Gazzah, R Bahleda, S Postel Vinay, C Smolenschi, A Hollebecque, J M Michot, V Ribrag, Y Loriot, S Champiat, K Ouali, C Massard, S Ponce Aix, M Bringuier, C Baldini
More than half of cancer cases occur in patients aged 65 years or older. The efficacy and safety of antibody drug conjugates (ADCs) in older patients remains an unclear subject as available evidence is limited. Geriatric population is underrepresented in clinical trials. Consequently, most of our knowledge regarding innovative therapeutics was studied on a younger population. In this review of published literature, we report the available information on efficacy, safety and pharmacokinetics of FDA approved ADCs for hematologic malignancies and solid tumors in the geriatric population...
November 23, 2023: Critical Reviews in Oncology/hematology
Fábio França Vieira E Silva, Vito Carlo Alberto Caponio, Mario Pérez-Sayáns, María Elena Padín-Iruegas, Marco Mascitti, Cintia Micaela Chamorro-Petronacci, José M Suaréz-Peñaranda, Alejandro Ismael Lorenzo-Pouso
BACKGROUND: Mortality is linked to tumor budding (TB) in certain neoplasms. TB as a relevant histopathological feature is conditioned by tumor site, a specific study on head and neck squamous cell carcinoma (HNSCC) is needed. METHODS: A comprehensive meta-analysis was undertaken to investigate the relationship between TB and HNSCC-related outcomes. RESULTS: Overall 42 studies were included. Patients harboring high TB reported an Overall Survival (OS) Hazard Ratio (HR) of 2...
November 19, 2023: Critical Reviews in Oncology/hematology
Yang Changjiang, Zhao Long, Lin Yilin, Wang Shan, Ye Yingjiang, Shen Zhanlong
Immune checkpoint inhibitors (ICIs) have paved a new pathway and revolutionized cancer treatment. Currently, ICIs have been extensively used for patients with advanced colorectal cancer (CRC), especially those harboring microsatellite instability (MSI). However, the efficacy of ICIs varies tremendously in different individuals, and some patients may not benefit from ICIs, which limits their clinical application. How to improve the efficacy of ICIs is an important issue to be solved. On the one hand, it is urgent to discover the predictive biomarkers to accurately screen the patients who gain benefit from ICIs, like microsatellite stability, tumor mutation burden (TMB), DNA polymerase ε/DNA polymerase δ1 mutations, and the expression of programmed death-ligand 1 (PD-L1)...
November 18, 2023: Critical Reviews in Oncology/hematology
Ali Zarezadeh Mehrabadi, Faezeh Shahba, Hossein Khorramdelazad, Nazanin Aghamohammadi, Milad Karimi, Kowsar Bagherzadeh, Majid Khoshmirsafa, Ramin Massoumi, Reza Falak
IL-1, plays a role in some pathological inflammatory conditions. This pro-inflammatory cytokine also has a crucial role in tumorigenesis and immune responses in the tumor microenvironment (TME). IL-1 receptor accessory protein (IL-1RAP), combined with IL-1 receptor-1, provides a functional complex for binding and signaling. In addition to the direct role of IL-1, some studies demonstrated that IL1-RAP has essential roles in the progression, angiogenesis, and metastasis of solid tumors such as gastrointestinal tumors, lung carcinoma, glioma, breast and cervical cancers...
November 20, 2023: Critical Reviews in Oncology/hematology
Xiao Tang, Yujie Niu, Jinli Jian, Yuancheng Guo, Yin Wang, Yu Zhu, Bei Liu
Ferroptosis, a novel form of iron-dependent cell death, has emerged as a potential avenue for promoting tumor cell death by causing cell membrane rupture and the accumulation of lipid peroxides (LPO) in the cell. Since its discovery in 2012, extensive research has been conducted to explore the mechanism of ferroptosis inducers, including erastin, sulfasalazine, and sorafenib. These compounds inhibit system XC-, while Ras-selective lethal small molecule 3 (RSL3) and FION2 specifically target GPX4 to promote ferroptosis...
November 16, 2023: Critical Reviews in Oncology/hematology
Amelia Barcellini, Tullio Golia D'Augè, Vincenzo Dario Mandato, Ilaria Cuccu, Angela Musella, Robert Fruscio, Maria Grazia Vitale, Ruby Martinello, Giorgia Mangili, Sandro Pignata, Innocenza Palaia
Gynecological neuroendocrine neoplasms are rare entities and can be divided into two groups: carcinoids and neuroendocrine carcinomas. Due to their rarity their management is not standardized. The aim of this work is to summarize and discuss the current literature evidence on this pathology. A scoping literature review was performed in multiple databases. Thirty-one studies were included: 30 case reports and one case series. Patients' age ranged between 28-92 years. Surgery was the most used treatment and the surgical approach included local excision (N=16/31; 51...
November 15, 2023: Critical Reviews in Oncology/hematology
Tanwei Yuan, Dominic Edelmann, Jakob N Kather, Ziwen Fan, Katrin E Tagscherer, Wilfried Roth, Melanie Bewerunge-Hudler, Alexander Brobeil, Matthias Kloor, Hendrik Bläker, Barbara Burwinkel, Hermann Brenner, Michael Hoffmeister
The research aimed to identify CpG-methylation-based prognostic biomarkers and prediction models for colorectal cancer (CRC) prognosis and validate them in a large external cohort. A systematic search was conducted, analyzing 298 unique CpGs and 12 CpG-based prognostic models from 28 studies. After adjustment for clinical variables, 48 CpGs and five prognostic models were confirmed to be associated with survival. However, the discrimination ability of the models was insufficient, with area under the receiver operating characteristic curves ranging from 0...
November 10, 2023: Critical Reviews in Oncology/hematology
Guocheng Wang, Yan Huang, Liang Zhou, Haojun Yang, Huang Lin, Shengfang Zhou, Zhengang Tan, Jun Qian
For patients diagnosed with advanced gastric or gastroesophageal cancer (AGC) that is not amenable to surgical intervention, the standard of care for first-line treatment consists of fluoropyrimidine and platinum-based chemotherapy. The incorporation of novel agents into these standard first-line regimens could potentially improve patient prognosis; options for such augmentations include both immune-based and targeted therapy combinations. To provide a comparative analysis of these different first-line combination treatments, a network meta-analysis was conducted...
November 9, 2023: Critical Reviews in Oncology/hematology
Zhihui Duan, Dandan Yang, Ping Yuan, Xiaoming Dai, Guodong Chen, Daichao Wu
Therapeutic cancer vaccines have shown promising efficacy in helping immunotherapy for cancer patients, but the systematic characterization of the clinical application and the method for improving efficacy is lacking. Here, we mainly summarize the classification of therapeutic cancer vaccines, including protein vaccines, nucleic acid vaccines, cellular vaccines and anti-idiotypic antibody vaccines, and subdivide the above vaccines according to different types and delivery forms. Additionally, we outline the clinical efficacy and safety of vaccines, as well as the combination strategies of therapeutic cancer vaccines with other therapies...
November 8, 2023: Critical Reviews in Oncology/hematology
Rui Wang, Aashiq Hussain, Quanquan Guo, Meimei Ma
DNA is highly immunogenic, both exogenous and endogenous DNA can activate the pathogen-associated molecular pattern (PAMP) and danger-associated molecular pattern (DAMP), respectively, and hence activate the evolutionarily conserved cGAS-STING pathway for inflammatory responses. The cGAS-STING signaling pathway plays a very important role in the pathogenesis and progression of neoplastic diseases. For cancer therapy, there are some discrepancies on whether cGAS-STING should be inhibited or activated. Deregulated cGAS-STING signaling pathway might be the origin and pathogenesis of tumor, understanding and modulating cGAS-STING signaling holds great promise for cancer therapy...
November 4, 2023: Critical Reviews in Oncology/hematology
Changjin Wu, Wentan Li, Hongyu Tao, Xiyan Zhang, Yu Xin, Ruomeng Song, Kaige Wang, Ling Zuo, Yuanyi Cai, Huazhang Wu, Wen Hui
BACKGROUND: Immunotherapies can substantially improve treatment efficacy, despite their high cost. A comprehensive overview of the cost-effectiveness analysis (CEA) of immune checkpoint inhibitors (ICIs) in patients with non-small cell lung cancer based on different tumor proportion scores (TPSs) was conducted. METHODS: PubMed, Embase, Cochrane Central Register of Controlled Trials, Health Technology Assessment Database, and NHS Economic Evaluation databases were searched from their inception until August 24, 2022...
November 4, 2023: Critical Reviews in Oncology/hematology
Boublikova Ludmila, Novakova Alena, Simsa Jaromir, Lohynska Radka
Current management of locally advanced rectal cancer achieves high cure rates, distant metastatic spread being the main cause of patients' death. Total neoadjuvant therapy (TNT) employs (chemo)radiotherapy and combined chemotherapy prior to surgery to improve the treatment outcomes. TNT has been shown to reduce significantly distant metastases, increase disease-free survival by 5 - 10% in 3 years, and finally also overall survival (≈ 5% in 7 years). It proved to double the rate of pathologic complete responses, making it an attractive strategy for non-operative management to avoid permanent colostomy in patients with distal tumors...
November 3, 2023: Critical Reviews in Oncology/hematology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.